OBJECTIVES: The Short Parkinson’s Evaluation Scale/Scales for Outcomes in Parkinson’s disease (SPES/SCOPA) was developed as a reliable and valid scale to evaluate motor impairment in Parkinson’s disease (PD) patients and can be completed in less time than the gold standard Unified Parkinson’s Disease Rating Scale (UPDRS). This study aimed to further investigate the reliability and validity of the SPES/SCOPA motor clinical examination, as relatively little research in the US has done so. METHODS: The BRAVURA study was designed to investigate order effects associated with the UPDRS motor examination at 2 centers in the US. Patients, stratified by center and previous Hoehn and Yahr (H&Y) stage, were randomly assigned to 1 of 2 UPDRS item sequences. All scale evaluations occurred during a single clinic visit. In addition to the 8-item SPES/SCOPA motor clinical examination and the 14-item UPDRS motor examination, scales included current H&Y stage and patient- and physician-rated Schwab and England Activities of Daily Living (ADL). Data were analyzed using Cronbach’s alpha and Spearman’s correlation. RESULTS: Complete data were available for 112 patients (mean time from diagnosis = 6.4 years). Relationships among the scales were comparable across the 2 experimental groups, thus data were pooled for these analyses; SPES/SCOPA mean score = 9.5 (SD = 5.2). The SPES/SCOPA demonstrated good internal reliability (alpha = 0.79). Construct validity was supported with the SPES/SCOPA correlating 0.76 with the UPDRS. Furthermore, the SPES/SCOPA correlated 0.47 with current H&Y stage and -0.39, -0.45 with patient- and physician-rated ADL, respectively. CONCLUSIONS: In this US sample of PD patients with varied disease severity, the SPES/SCOPA exhibited good psychometrics, including evidence of construct validity with the current standard of motor impairment measurement. The SPES/SCOPA also had good internal consistency and correlated with 3 broad evaluations of disease disability in a similar fashion to the UPDRS.